Nampota-Nkomba Nginache, Carey Megan E, Jamka Leslie P, Fecteau Natalie, Neuzil Kathleen M
Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi.
Cambridge Institute of Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, Cambridge, UK.
Open Forum Infect Dis. 2023 Jun 2;10(Suppl 1):S6-S12. doi: 10.1093/ofid/ofad022. eCollection 2023 May.
Typhoid fever is a serious disease that disproportionately impacts children in low-resource settings in sub-Saharan Africa, South and Southeast Asia, and the Western Pacific. The prevalence of antimicrobial-resistant strains of Typhi continue to increase worldwide. Two safe, effective, and cost-effective typhoid conjugate vaccines (TCVs) are World Health Organization-prequalified for the prevention of typhoid fever in children as young as 6 months. Typhoid conjugate vaccines have proven effectiveness in preventing drug-resistant Typhi and have been deployed successfully in outbreak response and routine immunization scenarios. Broad and equitable distribution of TCVs is essential to combat the spread and potentially devastating consequences of typhoid fever. It is vital to empower decision-makers in typhoid-endemic countries to introduce TCVs and for leaders to embrace this critical tool to prevent typhoid fever, slow the spread of drug-resistant Typhi strains, promote health equity, and save lives.
伤寒热是一种严重疾病，对撒哈拉以南非洲、南亚和东南亚以及西太平洋地区资源匮乏环境中的儿童影响尤为严重。全球范围内，耐药伤寒杆菌菌株的流行率持续上升。两种安全、有效且具有成本效益的伤寒结合疫苗已获得世界卫生组织预认证，可用于预防6个月及以上儿童的伤寒热。伤寒结合疫苗已被证明在预防耐药伤寒杆菌方面有效，并已成功应用于疫情应对和常规免疫接种场景。广泛且公平地分发伤寒结合疫苗对于抗击伤寒热的传播及其潜在的毁灭性后果至关重要。增强伤寒流行国家决策者引入伤寒结合疫苗的能力，并促使领导人接受这一预防伤寒热、减缓耐药伤寒杆菌菌株传播、促进健康公平及拯救生命的关键工具至关重要。
